Gsk Share Discussion Threads

[badtime] 25/4/2018 12:08

No online quote available

[rcturner2] 25/4/2018 12:05

GSK delivers Q1 sales of £7.2 billion, -2% AER, +4% CER

Total EPS 11.2p, -48% AER, -33% CER; Adjusted EPS 24.6p, -2% AER, +11% CER

Significant currency impact in the quarter reflecting movements in Sterling

[badtime] 25/4/2018 11:59

Apologies for misspelling your handle

[badtime] 25/4/2018 11:59

Oh blimey there you are :)

[abdullla] 25/4/2018 11:57

He is waiting for the results,thanks for asking,hopefully good news!

[badtime] 25/4/2018 11:49

What's happened to Abbdulah ..seems very quiet these days

[sicker] 25/4/2018 11:29

Should see an rns at 12.00 hopefully.

[romeike] 25/4/2018 10:27

Results are released later in the day in recognition of the large proportion of shareholders resident in the US. Hoping for big things from GSK, put a lot of faith in EW.

[tradermichael] 25/4/2018 08:01

GlaxoSmithKline PLC (GSK.LN) said Tuesday that the U.S. Food and Drug Administration has approved an expanded indication for its inhaler Trelegy Ellipta, a chronic obstructive pulmonary disease drug.
The London-based pharmaceutical and its partner Innoviva Inc. (INVA) said U.S. doctors can now use the medicine to treat a broader population of chronic obstructive pulmonary disease patients with airflow limitation, or patients who have experienced an acute worsening of respiratory symptoms.
GlaxoSmithKline said that the FDA's expanded indication was based on its Impact study and said that it would continue to analyze data from the study to demonstrate further benefits of the medicine.
Trelegy Ellipta was approved in the U.S. in September for the long-term, once-daily, treatment of chronic obstructive pulmonary disease patients.

[ygor705] 24/4/2018 18:00

Looks to be a reverse head and shoulders developing on the chart so you could well be correct NY Boy.

[ny boy] 24/4/2018 15:08

Sp tomorrow?

Could easily hit 1540p/1550p

Glaxosmithkline (GSK) chief executive Emma Walmsley has been under pressure during the drug major's share price decline, but investors have been bargain hunting in recent weeks.

Big hope here is for Shingrix, Glaxo's shingles vaccine. Launched last year, it's already grabbed a huge share of the US market, and analysts at UBS think it "will likely be bigger, faster than people think", triggering a "significant" earnings boost.

"The GSK growth story is still all about Trelegy, Shingrix and Consumer margin expansion," writes the broker, repeating its 'buy' rating and 1,600p price target.

[alphorn] 24/4/2018 11:55

Zantac is supposed to do the trick.

[jrphoenixw2] 24/4/2018 11:52

Hang-over pills [TM-Glaxo] post 2pm? ;)

[tradermichael] 24/4/2018 11:20

Champagne between 12:00 and 14:00 UK ........ ;0)

[tradermichael] 24/4/2018 11:19

There is a Webcast for GSK first quarter 2018 results
The live event will commence at 14:00 UK, 09:00 US EDT on Wednesday 25 April 2018

[tradermichael] 24/4/2018 11:18

GSK first quarter 2018 results for the period ended 31 March will be issued on Wednesday 25 April at approximately 12:00 UK, 07:00 US EDT.
The full results announcement will be available on GSK.com at that time.

[jrphoenixw2] 24/4/2018 10:23

Previous results (7-Feb) were out Noon/London. I'm expecting the same tomorrow.

[bilster1] 24/4/2018 09:38

Hi Michael - is it 12pm London time tomorrow for the Q1 results?

[alphorn] 24/4/2018 09:24

TM. I won't be following that approach! ;)

What will tomorrow hold? Not long to wait.

[jrphoenixw2] 24/4/2018 09:24

'GlaxoSmithKline will grow its earnings by 21.17% every year for the next few years.'

First red flag is forecasting any future stat to 2 decimal places. You can't forecast with anything like that accuracy. The second even more glaring one is projecting an average of estimates as something that 'will' happen.

[tradermichael] 24/4/2018 09:13

Yes, he took a simplistic approach (based on no real numbers, just a consensus of 'opinions'): He put a line of best fit through the forecasted earnings by market analysts. The slope of this line is the rate of earnings growth.

Anyway, results tomorrow!!

[alphorn] 24/4/2018 08:55

Thank you TM. It just did not make sense to me.

The article's earnings growth in 2017 of 68% comes from various changes (refer GSK financials) so IMO is completely misleading to quote. Earnings growth at CER was 4%. Projected earning's growth this year is 4-7% at CER depending upon Advair.

Compound growth at 21% for future years would be going some for a group of this size!


(Here are GSK's own numbers. Total EPS 31.4p, after accounting charges of £1.6 billion related to US tax reform. Adjusted EPS 111.8p, +11% AER, +4% CER, in line with 2017 guidance. For 2018 guidance, In the event of no substitutable generic competitor to Advair in the US, expect 2018 Adjusted EPS growth to be 4 to 7% CER
In the event of a mid-year introduction of a substitutable generic competitor to Advair in the US, expect full year 2018 US Advair sales of around £750 million at CER (US$1.30/£1) with Adjusted EPS flat to down 3% CER)

[tradermichael] 24/4/2018 07:03

#332 Alphorn - it was from this 'chartist':

[ny boy] 23/4/2018 23:54

Quite possible this quarter!